Patients diagnosed with diabetes are initiating GLP-1 treatment more quickly than ever before Since 2021, the average time between a diabetes diagnosis and the initiation of a GLP-1 therapy has decreased by about one month, underscoring how quickly these drugs have moved to the forefront of care
Retatrutides triple receptor activation provides extended benefits over Tirzepatide, which focuses only on GLP-1 and GIP
Vendors that refuse to provide current, third-party lab reports are a significant red flag in the industry
SeekPeptides provides detailed protocol guidance for transitioning between treatment and maintenance phases
Not only does it combine a physical restriction of calories, but some procedures also offer a hormonal benefit that helps patients eat less and lose weight rapidly, safely, and predictably
Frequently Asked Questions See If GLP-1 Treatment May Be Right for You A licensed provider can review your health history and weight-loss goals to help determine whether GLP-1 treatment is appropriate for you.
